Home » Clarification

Clarification

Jan 13, 2005
Premium

In Pharmacogenomics Reporter issue 1/6/2005, the article “FDA Clears Half of AmpliChip for Sale As an IVD; Rival Dx Shops Bear Down” characterized Paul Billings of LabCorp as saying “evidence, patient requests, quality, and liability concerns,” contributed to slow early P450 test demand. The text should have characterized these factors only as affecting demand.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Oct
02
Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
11
Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct
23
Featured Webinar

Perspectives on Small RNA Sequencing: Challenges and Complications of Small RNA Library Prep

Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.